SUSPECT ADVERSE REACTION REPORT																		IOI	MS	FO	RM
1-PAIRMAN ANTINALS TOLDITITY Des DETERMINENT Des DETERMINE	SUSPEC	CT ADVERSE I	REAC	CTION RE	POF	RT							<u> </u>				<u> </u>	— Т			
1. SUBSECT DRUGS Fraction 2. DUMPN 2007 2																	Ш	\perp			
PRIVACY PRIVAC				I. F	REAC	CTION	INFOR	MATION	l												
PRIVACY Vears Female May FEB 2025					-		3. SEX		-	_			_	-	8-12				E TO		
NOCUCED OR PRESCRIPTION Security of the control	PRIVACY	COSTARICA			Teal		Female		108	ay										٧	
Continued on Additional Information Page FIREALTION FIREALT	7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas) gaining weight with the dose of 1.2 mg [Weight increased]									INVOLVED OR PROLONGED INPATIENT HOSPITALISATION INVOLVED PERSISTENT OR SIGNIFICANT											
Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liragilutide 3.0 mg). (Continued on Additional Information Page) II. SUSPECT DRUG(\$) INFORMATION II. SUSPECT DRUG(\$) INFORMATION II. SUSPECT DRUG(\$) INFORMATION II. SUSPECT DRUG(\$) INFORMATION III. DOINT DRUG(\$) AND HISTORY 22. CONCOMITANT DRUG(\$) AND HISTORY (a.g. diagnostics, allergine, preparatory with last month of period deciprocytics of Deciprocytics (Current Condition duration not reported IV. MANUFACTURER INFORMATION 24. NAME AND ADDRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MANUFACTURER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MEPORTER NOVO NORGIS A'S. III. CONCOMITANT DRUG(\$) AND DRESS OF MEPORTER NAME AND ADDRESS OF MEPORTER III. CONCOMITANT DRUG(\$) AND DRESS OF MEPORTER NAME AND ADDRESS OF MANUFACTURER III. CONCOMITANT DRUG(\$) AND DRESS OF MEPORTER NAME AND ADDRESS OF MANUFACTURER III. CONCOMITANT DRUG(\$) AND DRESS OF MEPORTER III. CONCOMITANT DRUG(\$) AND DRESS OF MEPORTER III	Case Description	: ***This is an auto	gener	ated narrativ	ve***														₹		
Study description: Trial title: This is a 40 weeks digital patient support program with flocus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liragitutide 3.0 mg). (Continued on Additional Information Page) II. SUSPECT DRUG(S) INFORMATION III. SUSPECT DRUG(S) INFORMATION III. SUSPECT DRUG(S) INFORMATION III. DRUTPOSE(S) Include genetic name) #1) Saxenda (liragitutide 6 mg/mL) Solution for injection, 6 mg/mL (Continued on Additional Information Page) III. CONTINUE (Continued on Additional Information Page) III. CONTINUE (Continued on Additional Information Page) III. ROUTE(S) OF ADMINISTRATION #1) Subcutaineous III. ROUTE(S) OF ADMINISTRATION #1) Unknown III. CONCOMITANT DRUG(S) AND HISTORY 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (seclade Brose used to treat reaction) IV. MANUFACTURE R. INFORMATION Description Obesity (Obesity) IV. MANUFACTURER INFORMATION 246. MARE AND ADDRESS OF MANUFACTURER NOVO NOTGISK A'S. Lies Grimmeshave Vandaarnevel 114 Secloping Control (Control Condition Control Condition Control Con	Study ID: 828652	-My Healthy Journ																ENINC	3		
II. SUSPECT DRUG(S) (include genetic name)	Study description	: Trial title: This is a	40 w	eeks digital	patier	nt suppo	ort prograr	n with focu	ıs on	n exe	ercise	€,				COI	NGEN	JITAL Y			
14. SUBSECTIONLOGIS (include genetic same) 17. DAILY OSEKIS 18. DAILY OSEKIS 18. DAILY OSEKIS 18. DOUTE(S) OF ADMINISTRATION 18. DOUTE(S) OF ADMINISTRATION 19. DID REACTION 19. DID REA	motivation, nutrition	on & maintaining s	rategi	es (only for	patien	nts unde	Ū	0,		nal Ir	nform	atio	n Pa	ige)		ОТН	HER				
## 1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL 15. DAILY DOSE(S) ## 1) UNK ## 1) Subcutaneous 16. ROUTE(S) Or ADMINISTRATION ## 1) Subcutaneous 17. INDICATIONS) FOR USE ## 1) UNK 18. THERAPY DURATION ## 1) Unknown 18. THERAPY DURATION ## 1) Unknown 19. THERAPY DURATION ## 1) Unknown 22. CONCOMITANT DRUG(S) AND HISTORY 23. OTHER RELEVANT HISTORY. (e.g. diagnostics, ellergiese, preprincy with last mosth of period, etc.) Type of History, Notes Type of History, Notes Unknown to Ongoing 10. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER NOVO Nordisk A/S Lise Grimmeshave Vandataminey Both Schooling, DK-2860 DENMARK PTOR CONTROL NO. 1476054 24c. DATE RECEIVED BY MANUFACTURE STORY DATE STORY DURATION 24d. MFR CONTROL NO. 1476054 24d. REPORT SULPRE STORY DATE STORY DURATION 25d. NAME AND ADDRESS WITHHELD.				II. SUSF	PEC	T DRU	JG(S) IN	FORMA	TIO	N											
15. DAILY DOSE(S) 15.	` '	,	ution f	or injection 6	S ma/n	nl									AE	BATE .	AFTE		OPPING	3	
#1) UNIK #1) Subcutaneous	#1) Saxerida (iiraç	gradae o mg/mb) Soi	ulion	or injection, c	J IIIg/II	IIIL	(Cont	inued on Ad	ditio	nal Ir	nform	atio	n Pa	ige)	DF	RUG?					
#1) weight loss (Weight control) 18. THERAPY DURATION #1) OCT-2024 / Unknown 19. THERAPY DURATION #1) Unknown 19. THERAPY DURATION #1) Unknown VES														Σ	YE	s 🗀	NO		IA		
18. THERAPY DURATION																			₹		
#1) OCT-2024 / Unknown	#1) weight loss (W	Veight control)																			
22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) 23. OTHER RELEVANT HISTORY, (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Unknown to Ongoing IV. MANUFACTURER INFORMATION 249. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmenshave Vandtaarnsvej 114 Soeborg, Dk-2860 DENMARK Phone: +45 44448888 240. DATE RECEIVED BY MANUFACTURER Q4- JUL-2025 Q5 STUDY Q1 LITERATURE Q4- JUL-2025 Q3 STUDY Q1 LITERATURE Q4- JUL-2025 Q3 REPORT SOURCE Q5 STUDY Q1 LITERATURE Q4- JUL-2025 Q3 REPORT VPE 258. REPORT TYPE													YES NO NA								
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) From/To Dates Type of History / Notes Description Obesity (Obesity) IV. MANUFACTURER INFORMATION 24a. NAME AND ADDRESS OF MANUFACTURER NOVO Nordisk A/S Lise Grimmeshave Vanottaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1476054 24c. DATE RECEIVED BY MANUFACTURER O4-JUL-2025 AMERICAN ADDRESS OF REPORT TYPE 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.) AND H	IST	OR	Υ										
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1476054 24c. DATE RECEIVED BY MANUFACTURER 04-JUL-2025 DATE OF THIS REPORT 25a. REPORT TYPE 26. REMARKS Medically Confirmed: No 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	23. OTHER RELEVANT I From/To Dates	HISTORY. (e.g. diagnostics	allergies T	, pregnancy with ype of History / N Current Con	last mor lotes dition	nth of period	d, etc.) Description	(Obesity)													
24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1476054 24c. DATE RECEIVED BY MANUFACTURER 04-JUL-2025 DATE OF THIS REPORT 25a. REPORT TYPE 26a. REMARKS Medically Confirmed: No 25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.																					
Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888 24b. MFR CONTROL NO. 1476054 24c. DATE RECEIVED BY MANUFACTURER 04-JUL-2025 DATE OF THIS REPORT 25a. REPORT TYPE 25a. REPORT TYPE Medically Confirmed: No Medically Confirmed: No 45b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.	24a. NAME AND ADDRE	SS OF MANUFACTURER		IV. MAI	NUF/	<u>ACTU</u>			IOI	N								_			
1476054 24c. DATE RECEIVED BY MANUFACTURER 04-JUL-2025 DATE OF THIS REPORT 25a. REPORT TYPE NAME AND ADDRESS WITHHELD. PROFESSIONAL OTHER: DATE OF THIS REPORT 25a. REPORT TYPE	Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860	D DENMARK							ned:	No											
04-JUL-2025 DATE OF THIS REPORT 25a. REPORT TYPE 25a. REPORT TYPE				NO.			1						D.								
04-JUL-2025 DATE OF THIS REPORT 25a. REPORT TYPE 25a. REPORT TYPE	24c. DATE RECEIVED	24d. REPOR	r sourc				\dashv														
DATE OF THIS REPORT 25a. REPORT TYPE	Lat IIII coop																				
		25a. REPOR																			

Mfr. Control Number: 1476054

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Patient's height: 176 cm.
Patient's weight: 140 kg.

Patient's BMI: 45.196281.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "gaining weight with the dose of 1.2 mg(Weight gain)" beginning on FEB-2025, "lack of efficacy(Lack of drug effect)" beginning on FEB-2025 and concerned a 39 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from OCT-2024 to MAR-2025 for "weight loss",

Dosage Regimens:

Saxenda: ??-OCT-2024 to Not Reported, Not Reported to Not Reported, Not Reported to ??-MAR-2025;

Current Condition: Obesity.

Lab Data included:

Lab Data Test as Reported: weight

Test Name: Weight

Comments: From an unknown date after patient began to notice that the patient was gaining weight with the dose of 1.2 mg.

Lab Data Test as Reported: weight

Test Name: Weight

Comments: On unknown date the patient has lost 3kg of weight

Batch Numbers:

Saxenda: ASKU, ASKU, ASKU;

Action taken to Saxenda was reported as Product discontinued due to AE.

On MAR-2025 the outcome for the event "gaining weight with the dose of 1.2 mg(Weight gain)" was Recovered. On MAR-2025 the outcome for the event "lack of efficacy(Lack of drug effect)" was Recovered.

Reporter's causality (Saxenda) -

gaining weight with the dose of 1.2 mg(Weight gain): Unknown

lack of efficacy(Lack of drug effect) : Unknown

Company's causality (Saxenda) -

gaining weight with the dose of 1.2 mg(Weight gain): Possible

lack of efficacy(Lack of drug effect): Possible

13. Lab Data

#	Date	Test / Assessment / Notes	Results	Normal High / Low
1		Weight		
		From an unknown date after patient be with the dose of 1.2 mg.	egan to notice that the patie	nt was gaining weight
2		Weight		
		On unknown date the patient has lost	3kg of weight	

13. Relevant Tests

On unknown date the patient has lost 3kg of weight

From an unknown date after patient began to notice that the patient was gaining weight with the dose of 1.2 mg.

		Mf	r. Control Number: 1476054							
ADDITIONAL INFORMATION										
14-19. SUSPECT DRUG(S) continued										
14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION							
#1) Saxenda (liraglutide 6 mg/mL) Solution	1.2 mg (increased dose);	weight loss (Weight control)	Unknown;							
for injection, 6 mg/mL; Regimen #2	Subcutaneous		Unknown							
#1) Saxenda (liraglutide 6 mg/mL) Solution	3 mg, qd; Subcutaneous	weight loss (Weight control)	Unknown / MAR-2025;							
for injection, 6 mg/mL; Regimen #3			Unknown							